Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(33%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

terminated117%
recruiting233%
completed350%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis

NCT07542808
recruitingphase_2

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

NCT03673748
terminatedphase_1

Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders

NCT01540292
completedphase_2

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

NCT02501811
completedphase_1

Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis

NCT04823000
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07542808Phase 2

An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Recruiting
NCT03673748Phase 2

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Recruiting
NCT01540292Phase 1

Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders

Terminated
NCT02501811Phase 2

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

Completed
NCT04823000Phase 1

Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis

Completed
NCT04821479Phase 1

Repeated Mesenchymal Stem Cell Injections in ALS

Completed

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6